Therefore, we have conducted this study in a cohort of 918 breast and ovarian cancer patients from Middle Eastern ethnicity to investigate the prevalence of germline PALB2 PVs and LPVs in breast cancer and ovarian cancer patients, and their molecular and clinicopathological characteristics in this population. Here, PALB2 is linked to ovarian carcinoma.